Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820398 | 0.95 | LMNA (0.43) | HTR7LMNANPC1KMT2AMEN1 | |
| SCHEMBL820203 | 0.94 | HTR7 (0.48) | HTR7LMNANPC1KMT2AMEN1 | |
| SCHEMBL820612 | 0.93 | LMNA (0.47) | PDPK1LMNANPC1KMT2AMEN1 | |
| SCHEMBL820185 | 0.90 | PDPK1 (0.44) | PDPK1LMNANPC1KMT2AMEN1 | |
| SCHEMBL820406 | 0.90 | HTR7 (0.44) | HTR7LMNANPC1KMT2AMEN1 | |
| SCHEMBL820183 | 0.89 | L3MBTL1 (0.43) | HTR7LMNAKMT2AMEN1L3MBTL1 | |
| SCHEMBL820625 | 0.89 | L3MBTL1 (0.49) | LMNANPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL820403 | 0.88 | HPGD (0.44) | HTR7LMNANPC1KMT2AMEN1 | |
| SCHEMBL820811 | 0.86 | HTR7 (0.40) | HTR7LMNANPC1KMT2AMEN1 | |
| SCHEMBL820228 | 0.85 | LMNA (0.49) | PDPK1LMNANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222177-B2 | Catalyst and reaction process | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | ME1, MAL2, ME2 | HTR7 1983/4885PDPK1 4324/4885LMNA 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.